158078-04-7

Basic information

• Product Name: [(3aR,4R,6R,6aR)-6-{4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methanol
• Synonyms: [(3aR,4R,6R,6aR)-6-{4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methanol;4-Chloro-7-(2,3-O-isopropylidene-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine;((3aR,4R,6R,6aR)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol;((3aR,4R,6R,6aR)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol(WXC06289)
• CAS NO: 158078-04-7
• Molecular Formula: C₁₄H₁₆ClN₃O₄
• Molecular Weight: 325.74754
• Mol File: 158078-04-7.mol

Chemical Properties

• Boiling Point: 513.5±50.0 °C(Predicted)
• Appearance: /
• Density: 1.68±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 14.14±0.10(Predicted)
• CAS DataBase Reference: [(3aR,4R,6R,6aR)-6-{4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methanol(CAS DataBase Reference)
• NIST Chemistry Reference: [(3aR,4R,6R,6aR)-6-{4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methanol(158078-04-7)
• EPA Substance Registry System: [(3aR,4R,6R,6aR)-6-{4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methanol(158078-04-7)

Safety Data

• Hazardous Substances Data: 158078-04-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
[(3aR,4R,6R,6aR)-6-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methanol is used as a potential bioactive compound for the development of new drugs due to its unique molecular structure and the presence of various functional groups that may interact with biological targets.
Used in Agrochemical Industry:
This chemical may also be utilized as a building block in the synthesis of agrochemical compounds, given its complex structure and the possibility of its reactivity with other molecules, which could lead to the creation of novel pesticides or herbicides.
Further research and analysis are essential to fully understand the potential uses and effects of [(3aR,4R,6R,6aR)-6-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methanol in these industries and to determine its suitability for specific applications.

Upstream product

• 115479-39-5 4-chloro-7-<5-O-<(1,1-dimethylethyl)dimethylsilyl>-2,3-O-(1-methylethylidene)-β-D-ribofuranosyl>-7H-pyrrolo<2,3-d>pyrimidine 
• 1000982-02-4 tert-butyl(((3aR,4R,6aR)-6-chloro-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)dimethylsilane 
• 217309-46-1 5-(tert-butyldimethylsilyloxy)-2,3-isopropylidenedioxy-D-ribofuranose 
• 67814-68-0 2,3-O-isopropylidene-D-ribofuranose 
• 50-69-1 D-ribose 
• 16754-80-6 4-chloro-7-(β-D-ribofuranosyl)-7H-pyrrolo<2,3-d>pyrimidine 
• 77-76-9 2,2-dimethoxy-propane 

Downstream Products

• 2040291-27-6 (2R,3R,4S,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-hydroxy(phenyl)methyl)tetrahydrofuran-3,4-diol 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The present disclosure describes novel heterocyclic PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorders are also described.

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The present disclosure describes novel PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorde

NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

5'-SUBSTITUTED NUCLEOSIDE ANALOGS

The present invention relates to novel 5-substituted nucleoside compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer, in particular glioblastomas, melanoma, sarcomas, gastric cancer, pancreatic cancer, cholangiocarcinoma, bladder cancer, breast cancer, non-small cell lung cancer, leukemias including acute myeloid leukemia, and lymphomas.

SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS

Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

INHIBITORS OF E1 ACTIVATING ENZYMES

This invention relates to compounds that inhibit El activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.